Is It Too Late to Buy This Warren Buffett Stock That Has Soared in 2026?

Occidental reported strong fourth-quarter operating momentum, including 1.481 Mboed production in Q4 and a full-year record of 1.434 million boed, alongside $11.6 billion of operating cash flow before working capital and $4.3 billion of free cash flow. The company also reduced debt to about $15 billion after selling OxyChem to Berkshire Hathaway for $9.7 billion and lifted its quarterly dividend by 8%. Shares are up about 37% year to date, but the article notes valuation is less compelling after the run-up, with a forward P/E around 12.5 and 2026 capex guided at $5.5 billion to $5.9 billion.

Analysis

OXY’s setup is less about “cheap energy” and more about a de-risked equity story after the balance-sheet reset. The OxyChem sale removes a cyclical but diversifying cash source, so the residual equity is now a cleaner call option on upstream cash generation; that usually compresses the diversification multiple but can expand the free-cash-flow multiple if investors start underwriting a more durable capital return framework. The market may be extrapolating peak commodity conditions into normalized valuation, so the next leg likely depends more on buybacks/dividend signaling than on another production beat.

Second-order winners are the large shareholders and the entire domestic oil service stack. If OXY uses the improved leverage to keep spending near maintenance rather than growth, that is subtly bearish for high-cost oilfield services and bullish for peers with stronger capital discipline, because industry supply growth remains constrained even as headline production hits records. The real marginal beneficiary of sustained $80-$90 crude is not necessarily OXY alone, but the lowest-decline, lowest-cost producers that can convert every incremental barrel into shareholder distributions with less reinvestment drag.

The main risk is that the stock now has less room for operational disappointment: a modest oil pullback, a refining margin slip, or even a small capex overrun can hit both earnings and sentiment at the same time. Over the next 1-3 months, watch the Brent-WTI spread, OPEC messaging, and any signs that U.S. shale growth is re-accelerating; those are the quickest ways this trade can de-rate. Over a 6-12 month horizon, the consensus may be missing that Berkshire’s historical average entry price created a psychological anchor that public-market buyers do not have — meaning the current shareholder base is more price-sensitive and likely to sell into volatility.

Key Decisions for Investors

• Trim long OXY into strength and re-enter on a 7-10% pullback; upside from here looks more like mid-teens total return than a rerating breakout unless crude stays elevated for several quarters.
• Favor a pair trade: long higher-quality, lower-decline E&Ps (e.g., FANG/XEC) versus short OXY on a 3-6 month view; OXY’s cleaner story is already partly priced, while peers may offer better FCF conversion per dollar of capital employed.
• Use a bullish options structure only if seeking convexity: buy OXY 6-9 month put spreads to express a view that the market is underpricing commodity downside; risk/reward improves materially if crude mean-reverts 10-15%.
• For income-oriented accounts, own BRK.B rather than OXY outright; the Berkshire stake plus cash recycle from the OxyChem transaction gives you energy exposure with lower single-name commodity beta.
• Monitor capex guidance and quarterly buyback cadence closely; if capital returns do not accelerate over the next 1-2 quarters, the stock can de-rate even with stable production.